Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons - 1 Jun 2013

Kamburova E G, Koenen H J P M, Borgman K J E, ten Berge I J, Joosten I, Hilbrands L B

Abstract excerpt

A single dose of the anti-CD20 monoclonal antibody rituximab induces a nearly complete B cell depletion in peripheral blood, but not in secondary lymphoid organs. Modulation of this remaining B cell population due to rituximab treatment may contribute to the therapeutic effects of rituximab. To assess the in vivo effects of rituximab we used lymph nodes (LNs) collected during renal transplant surgery in patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Murine-Derived
Share to Antigens, CD20

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Graft Rejection

Share to Immunologic Factors

Share to Kidney Transplantation

Share to Lymphocyte Depletion

Share to Rituximab

Share to Spleen

Source

Identifiers

PMID: 23570303
DOI: 10.1111/ajt.12220

Genes

ABO

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function.PMID 23570303Read ↗

Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis.Semantic proximity Read ↗

In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells.Semantic proximity Read ↗

Depletion of functionally active CD20+ T cells by rituximab treatment.Semantic proximity Read ↗

Kinetic analysis of changes in T- and B-lymphocytes after anti-CD20 treatment in renal pathology.Semantic proximity Read ↗

B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels.Semantic proximity Read ↗

Depletion of peripheral blood B cells with Rituximab and phenotype characterization of the recovering population in a patient with follicular lymphoma.Semantic proximity Read ↗

The immunological phenotype of rituximab-sensitive chronic graft-versus-host disease: a phase II study.Semantic proximity Read ↗

Sensitive B-cell receptor repertoire analysis shows repopulation correlates with clinical response to rituximab in rheumatoid arthritisSemantic proximity Read ↗

Selection of B-cell chronic lymphocytic leukemia cell variants by therapy with anti-CD20 monoclonal antibody rituximab.Semantic proximity Read ↗

Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy.Semantic proximity Read ↗

Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab.Semantic proximity Read ↗

Enhancement of Rituximab-induced cell death by the physical association of CD20 with CD40 molecules on the cell surface.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.